SDS

NiagaraNonAerosolSprayStarch
SafetyDataSheet 
AccordingToFederalRegister/Vol.77,No.58/Monday,March26,2012/RulesAndRegulations
RevisionDate:06/08/2016 DateofIssue:06/08/2016 Version:1.0
06/08/2016 EN(EnglishUS) 1/5
SECTION1:IDENTIFICATION
1.1.ProductIdentifier
ProductForm:Mixture
ProductName:NiagaraNonAerosolSprayStarch
ProductCode:08580;08586
*Thisdocumentisintendedtobeusedforsafetyintheworkplaceonly,andisnotaconsumerdocument.
1.2.IntendedUseoftheProduct
Fabricfinish.
1.3.Name,Address,andTelephoneoftheResponsibleParty
NiagaraStarchCompany
1025W8thSt.
KansasCity,MO64101USA
T:18163291300
www.niagarastarch.com
1.4.EmergencyTelephoneNumber
EmergencyNumber : 18004249300(CHEMTREC)

SECTION2:HAZARDSIDENTIFICATION
2.1.ClassificationoftheSubstanceorMixture
GHSUSClassification
Notclassified
2.2.LabelElements
GHSUSLabelingNolabelingapplicable
2.3.OtherHazards
Exposuremayaggravatepreexistingeye,skin,orrespiratoryconditions.

2.4.UnknownAcuteToxicity(GHSUS)Nodataavailable
SECTION3:COMPOSITION/INFORMATIONONINGREDIENTS
3.1. Substances
Notapplicable
3.2. Mixture
Name ProductIdentifier %(w/w)
Polyethyleneglycol (CASNo)25322683 <0.1
Thespecificchemicalidentityand/orexactpercentageofcompositionhavebeenwithheldasatradesecret[29CFR1910.1200].
ArangeofconcentrationasprescribedbytheControlledProductsRegulationshasbeenusedwherenecessary,duetovarying
composition.
SECTION4:FIRSTAIDMEASURES
4.1.DescriptionofFirstaidMeasures
General:Nevergiveanythingbymouthtoanunconsciousperson.Ifyoufeelunwell,seekmedicaladvice(showthelabelwhere
possible).
Inhalation:Whensymptomsoccur:gointoopenairandventilatesuspectedarea.Obtainmedicalattentionifbreathingdifficulty
persists.
SkinContact:Removecontaminatedclothing.Drenchaffectedareawithwaterforatleast15minutes.Obtainmedicalattentionif
irritationdevelopsorpersists.
EyeContact:Rinsecautiouslywithwaterforatleast15minutes.Removecontactlenses,ifpresentandeasytodo.Continuerinsing.
Obtainmedicalattention.
Ingestion:Rinsemouth.DoNOTinducevomiting.Obtainmedicalattention.
4.2.MostImportantSymptomsandEffectsBothAcuteandDelayed
General:Notexpectedtopresentasignificanthazardunderanticipatedconditionsofnormaluse.

Inhalation:Prolongedexposuremaycauseirritation.


Summary of content (5 pages)